Elsevier

Biochemical Pharmacology

Volume 53, Issue 12, 15 June 1997, Pages 1855-1866
Biochemical Pharmacology

Research paper
Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression

https://doi.org/10.1016/S0006-2952(97)82448-3Get rights and content

Abstract

Resistance to some (lipophilic) antifolates has been associated with P-glycoprotein (P-gp)mediated multidrug resistance (MDR). A possible relationship with non-P-gp MDR has not been established. We studied resistance to antifolates in SW-1573 human lung carcinoma cells, a P-gp overexpressing variant SW-1573/2R160 and a multidrug resistance protein (MRP) overexpressing variant SW-1573/2R120. In this study, thymidylate synthase (TS) inhibitors with different properties concerning the efficiency of membrane transport and the efficiency of polyglutamylation were tested for cross-resistance in SW-1573/2R120 and SW-1573/2R160 cells. Growth inhibition patterns in this cell line panel were measured by the Sulforhodamine B (SRB) assay. Resistance factors for TS inhibitors were: 2.4 and 0.4 for 5-fluorouracil (5FU), 18.8 and 8.8 for ZD1694, 17 and 0.7 for AG337, and 40 and 8.3 for BW1843U89 in SW-1573/2R160 and SW-1573/2R120, respectively. This study showed changes in the TS enzyme kinetics during the induction of doxorubicin resistance in both SW-1573 variants, resulting in 2-fold lower Km values for 2′-deoxyuridine-5′-monophosphate (dUMP) in both resistant variants compared to the parental cell line. TS activity, TS protein induction and TS mRNA expression all had 2-fold increased in the SW-1573/2R120 compared to the SW-1573/2R160. 3H-MTX influx was 2-fold lower in SW-1573/2R160 cells compared to SW-1573/2R120 and SW-1573 cells. In the SW-1573/2R160 cell line, an aberrant intracellular trafficking towards the target TS was observed, compared to SW-1573/2R120 and SW-1573 cells as measured by the TS in situ assay. The rate of TS inhibition by the TS inhibitors used in this study was similar in all cell lines. In conclusion, collateral sensitivity to 5FU and the lipophilic AG337 and cross-resistance to other antifolates were observed in non-P-gp MDR SW-1573/2R120 cells, as well as resistance to all antifolates in P-gp SW-1573/2R160 cells. The mechanism of resistance in SW-1573/2R160 cells possibly involves reduced influx and changes in intracellular trafficking routes. For the SW-1573/2R120 cell line, several changes related to the TS enzyme possibly play a role in the observed cross-resistance and collateral sensitivity pattern.

References (63)

  • K Keyomarsi et al.

    Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells

    J Biol Chem

    (1988)
  • G Pizzorno et al.

    Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil

    Biochem Pharmacol

    (1995)
  • B-F Lin et al.

    Expression of Escherichia coli folylpolyglutamate synthetase in the Chinese hamster ovary cell mitochondrion

    J Biol Chem

    (1994)
  • SR Schlemmer et al.

    Retentiveness of methotrexate polyglutamates in cultured L1210 cells; evidence against a role for mediated plasma membrane transport outward

    Biochem Pharmacol

    (1993)
  • G Jansen et al.

    Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates

    J Biol Chem

    (1990)
  • M Saxena et al.

    Identification of efflux systems for large anions and anionic conjugates as the mediators of methotrexate efflux in L1210 cells

    Biochem Pharmacol

    (1996)
  • P Borst et al.

    Drug resistance

  • G.J. Peters et al.

    Resistance to antimetabolites

  • F.M. Sirotnak

    Determinants of resistance to antifolates: Biochemical phenotypes, their frequency of occurence and circumvention

    NCI Monographs

    (1987)
  • J.R. Bertino

    Ode to Methotrexate

    J Clin Oncol

    (1993)
  • H.J. Broxterman et al.

    The impact of transport-associated resistance in anticancer chemotherapy

  • C.E. Grant et al.

    Overexpression of multidrug resistanceassociated protein (MRP) increases resistance to natural product drugs

    Cancer Res

    (1994)
  • H.J. Broxterman et al.

    Multidrug resistance proteins and other drug transport-related resistance to natural product agents

    Curr Opion Oncol

    (1995)
  • H.M. Pinedo et al.

    P-glycoprotein—A marker of cancer-cell behavior

    New Eng J Med

    (1995)
  • H.M. Pinedo et al.

    Fluorouracil: Biochemistry and pharmacology

    J Clin Oncol

    (1988)
  • G.J. Peters et al.

    Thymidylate synthase inhibition after administration of 5-fluorouracil with or without leucovorin; implications for treatment with 5-fluorouracil

    J Clin Oncol

    (1994)
  • C.P. Spears et al.

    Thymidylate synthase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil

    Cancer Res

    (1984)
  • S.M. Swain et al.

    Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer

    J Clin Oncol

    (1989)
  • A.L. Jackman et al.

    ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study

    Cancer Res

    (1991)
  • D.S. Duch et al.

    Biochemical and cellular pharmacology of 1843U89, a novel Benzoquinazoline inhibitor of thymidylate synthase

    Cancer Res

    (1993)
  • R.C. Jackson et al.

    Molecular design of thymidylate synthase inhibitors

  • Cited by (0)

    This study was supported by the Dutch Cancer Society, grant IKA VU 93-627. The authors would like to thank Dr. H. J. Broxterman and Ms. N. Eikelboom for critical reading of the manuscript and Mr. P. Noordhuis for expert technical assistance.

    View full text